Grail Inc Earnings Reports

Grail Inc delivered Q1 revenue of $31.8M, driven by Galleri test growth, while reporting a net loss of $106.2M. Adjusted EBITDA improved significantly year-over-year. The company maintains a strong cash position to support operations through 2028.

GRAIL reported a 26% increase in fourth-quarter revenue, reaching $38.3 million, with Galleri revenue growing 39% to $31.6 million. The company's net loss for the quarter was $97.1 million. GRAIL ended the year with a strong cash position of $767 million, extending its operational runway into 2028.

GRAIL reported a 38% increase in total revenue to $28.7 million, with Galleri revenue growing by 52% to $25.4 million. The company's net loss was $125.7 million, while adjusted EBITDA showed an improvement. Over 250,000 Galleri tests have been sold since launch, and the company is focusing on cost management and advancing registrational studies.

GRAIL reported a 43% year-over-year increase in revenue to $32.0 million for the second quarter of 2024. The company's strategic update includes reducing overall spend and focusing on core multi-cancer early detection priorities, which is expected to extend the cash runway into 2028.